scholarly journals Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

2017 ◽  
Vol 18 (6) ◽  
pp. 770-778 ◽  
Author(s):  
Angela Alistar ◽  
Bonny B Morris ◽  
Rodwige Desnoyer ◽  
Heidi D Klepin ◽  
Keyanoosh Hosseinzadeh ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Dose Escalation ◽  
Phase 1 ◽  
Metastatic Pancreatic Cancer ◽  
Single Centre ◽  
Open Label ◽  
Phase 1 Trial ◽  
Label Dose

scholarly journals A phase 1/2, open‐label, dose‐escalation study of midostaurin in children with relapsed or refractory acute leukaemia

2018 ◽  
Vol 185 (3) ◽  
pp. 623-627 ◽  
Author(s):  
C. Michel Zwaan ◽  
Stefan Söderhäll ◽  
Benoit Brethon ◽  
Matteo Luciani ◽  
Carmelo Rizzari ◽  
...  
Keyword(s):  
Dose Escalation ◽  
Acute Leukaemia ◽  
Phase 1 ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors

2018 ◽  
Vol 81 (4) ◽  
pp. 727-737 ◽  
Author(s):  
Frederik Marmé ◽  
Carlos Gomez-Roca ◽  
Kristina Graudenz ◽  
Funan Huang ◽  
John Lettieri ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Dose Escalation ◽  
Phase 1 ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose
Sign in / Sign up

Export Citation Format

Share Document